Recursion Pharmaceuticals (RXRX) Intangibles (2020 - 2026)

Recursion Pharmaceuticals has reported Intangibles for 7 years, with the latest figure at $294.1 million in Q1 2026.

• For the quarter ending Q1 2026, Intangibles fell 12.42% year-over-year to $294.1 million; the trailing twelve-month figure through Mar 2026 stood at $294.1 million (down 12.42% YoY), and the FY2025 full-year result was $309.9 million, down 7.73% from the prior year.
• Intangibles for Q1 2026 stood at $294.1 million, down from $309.9 million in the prior quarter.
• The five-year high for Intangibles was $341.3 million in Q2 2025, with the low at $1.2 million in Q2 2022.
• Historically, Intangibles has averaged $127.6 million across 5 years, with a median of $38.2 million in 2024.
• Annual changes were most pronounced in 2023 — Intangibles soared 3367.72% — and 2024, when it declined 13.6%.
• Recursion Pharmaceuticals' Intangibles stood at $1.3 million in 2022, then soared by 2690.43% to $36.4 million in 2023, then surged by 821.59% to $335.9 million in 2024, then decreased by 7.73% to $309.9 million in 2025, then slipped by 5.11% to $294.1 million in 2026.
• The last three Intangibles figures came in at $294.1 million (Q1 2026), $309.9 million (Q4 2025), and $322.3 million (Q3 2025), per Business Quant data.